{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:05:59Z","timestamp":1780412759268,"version":"3.54.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T00:00:00Z","timestamp":1435017600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s11096-015-0150-z","type":"journal-article","created":{"date-parts":[[2015,6,22]],"date-time":"2015-06-22T14:26:50Z","timestamp":1434983210000},"page":"709-716","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["The role of the pharmacist in the selection and use of over-the-counter proton-pump inhibitors"],"prefix":"10.1007","volume":"37","author":[{"given":"Helen F.","family":"Boardman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Heeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,23]]},"reference":[{"issue":"6","key":"150_CR1","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1542-3565(05)00153-9","volume":"3","author":"M Camilleri","year":"2005","unstructured":"Camilleri M, Dubois D, Coulie B, Jones M, Kahrilas PJ, Rentz AM, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol. 2005;3(6):543\u201352.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"6","key":"150_CR2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/dote.12007","volume":"26","author":"FK Friedenberg","year":"2013","unstructured":"Friedenberg FK, Makipour K, Palit A, Shah S, Vanar V, Richter JE. Population-based assessment of heartburn in urban Black Americans. Dis Esophagus. 2013;26(6):561\u20139.","journal-title":"Dis Esophagus"},{"issue":"5","key":"150_CR3","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1053\/j.gastro.2012.08.002","volume":"143","author":"AF Peery","year":"2012","unstructured":"Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143(5):1179\u201387.","journal-title":"Gastroenterology"},{"issue":"5","key":"150_CR4","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2036.2006.02811.x","volume":"23","author":"JF Bretagne","year":"2006","unstructured":"Bretagne JF, Honnorat C, Richard-Molard B, Caekaert A, Barthelemy P. Comparative study of characteristics and disease management between subjects with frequent and occasional gastro-oesophageal reflux symptoms. Aliment Pharmacol Ther. 2006;23(5):607\u201316.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"150_CR5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1365-2036.2003.01737.x","volume":"18","author":"WM Wong","year":"2003","unstructured":"Wong WM, Lai KC, Lam KF, Hui WM, Hu WH, Lam CL, et al. Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther. 2003;18(6):595\u2013604.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"150_CR6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/MEG.0b013e3282f2a5bd","volume":"20","author":"R Jones","year":"2008","unstructured":"Jones R, Ballard K. Healthcare seeking in gastro-oesophageal reflux disease: a qualitative study. Eur J Gastroenterol Hepatol. 2008;20(4):269\u201375.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"150_CR7","doi-asserted-by":"crossref","unstructured":"French-Belgian Consensus Conference on Adult Gastro-oesophageal Reflux Disease \u2018Diagnosis and Treatment\u2019: report of a meeting held in Paris, France, on 21\u201322 January 1999. The Jury of the consensus conference. Eur J Gastroenterol Hepatol. 2000;12(1):129\u201337.","DOI":"10.1097\/00042737-200012010-00024"},{"issue":"6","key":"150_CR8","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1053\/j.gastro.2003.09.030","volume":"125","author":"DK Rex","year":"2003","unstructured":"Rex DK, Cummings OW, Shaw M, Cumings MD, Wong RK, Vasudeva RS, et al. Screening for Barrett\u2019s esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125(6):1670\u20137.","journal-title":"Gastroenterology"},{"key":"150_CR9","unstructured":"Coping With Common GI Symptoms in the Community: a Global Perspective on Heartburn, Constipation, Bloating, and Abdominal Pain\/Discomfort [Internet]. World Gastroenterology Organisation; [updated 2013 May]. http:\/\/www.worldgastroenterology.org\/assets\/export\/userfiles\/2013_FINAL_Common%20GI%20Symptoms%20_long.pdf ."},{"key":"150_CR10","unstructured":"Dyspepsia and Gastro-Oesophageal Reflux Disease [Internet]. National Institute for Health and Care Excellence; [updated 2014]. http:\/\/www.nice.org.uk\/guidance\/cg184 ."},{"issue":"3","key":"150_CR11","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ajg.2012.444","volume":"108","author":"PO Katz","year":"2013","unstructured":"Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308\u201328.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"150_CR12","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000235953","volume":"80","author":"S Haag","year":"2009","unstructured":"Haag S, Andrews JM, Katelaris PH, Gapasin J, Galmiche JP, Hunt R, et al. Management of reflux symptoms with over-the-counter proton pump inhibitors: issues and proposed guidelines. Digestion. 2009;80(4):226\u201334.","journal-title":"Digestion"},{"key":"150_CR13","volume-title":"Quantitative study 2013","author":"The Epposi Barometer: Consumer Perceptions of Self Care in Europe","year":"2014","unstructured":"The Epposi Barometer: Consumer Perceptions of Self Care in Europe. Quantitative study 2013. Brussels: Epposi; 2014."},{"issue":"8","key":"150_CR14","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","volume":"101","author":"N Vakil","year":"2006","unstructured":"Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900\u201320.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"150_CR15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/archinte.161.1.45","volume":"161","author":"C Farup","year":"2001","unstructured":"Farup C, Kleinman L, Sloan S, Ganoczy D, Chee E, Lee C, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med. 2001;161(1):45\u201352.","journal-title":"Arch Intern Med"},{"issue":"6","key":"150_CR16","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/gutjnl-2012-304269","volume":"63","author":"HB El-Serag","year":"2014","unstructured":"El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871\u201380.","journal-title":"Gut"},{"issue":"6","key":"150_CR17","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/2327-6924.12133","volume":"26","author":"JW McRorie Jr","year":"2014","unstructured":"McRorie JW Jr, Gibb RD, Miner PB Jr. Evidence-based treatment of frequent heartburn: the benefits and limitations of over-the-counter medications. J Am Assoc Nurse Pract. 2014;26(6):330\u20139.","journal-title":"J Am Assoc Nurse Pract"},{"issue":"5","key":"150_CR18","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/apt.12857","volume":"40","author":"A Ruigh De","year":"2014","unstructured":"De Ruigh A, Roman S, Chen J, Pandolfino JE, Kahrilas PJ. Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study. Aliment Pharmacol Ther. 2014;40(5):531\u20137.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"150_CR19","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/MOG.0b013e32833f2010","volume":"26","author":"ML Schubert","year":"2010","unstructured":"Schubert ML. Gastric secretion. Curr Opin Gastroenterol. 2010;26(6):598\u2013603.","journal-title":"Curr Opin Gastroenterol"},{"key":"150_CR20","first-page":"CD002095","volume":"5","author":"KE Sigterman","year":"2013","unstructured":"Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;5:CD002095.","journal-title":"Cochrane Database Syst Rev"},{"key":"150_CR21","unstructured":"Drugs for Acid Related Disorders [Internet]. Association of the European Self-Medication Industry; [updated 2015]. http:\/\/www.aesgp.eu\/facts-figures\/otc-ingredients\/ ."},{"key":"150_CR22","unstructured":"Prescription to Over-the-Counter (OTC) Switch List [Internet]. US Food and Drug Administration; [updated 2014]. http:\/\/www.fda.gov\/aboutfda\/centersoffices\/officeofmedicalproductsandtobacco\/cder\/ucm106378.htm ."},{"key":"150_CR23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-230X-12-18","volume":"12","author":"D Pouchain","year":"2012","unstructured":"Pouchain D, Bigard MA, Liard F, Childs M, Decaudin A, McVey D. Gaviscon(R) vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. A direct comparative randomised trial. BMC Gastroenterol. 2012;12:18.","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"150_CR24","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s11096-011-9489-y","volume":"33","author":"G Holtmann","year":"2011","unstructured":"Holtmann G, Bigard MA, Malfertheiner P, Pounder R. Guidance on the use of over-the-counter proton pump inhibitors for the treatment of GERD. Int J Clin Pharm. 2011;33(3):493\u2013500.","journal-title":"Int J Clin Pharm"},{"issue":"10","key":"150_CR25","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3109\/00365529709011211","volume":"32","author":"TL Venables","year":"1997","unstructured":"Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol. 1997;32(10):965\u201373.","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"150_CR26","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0016-5107(03)02011-X","volume":"58","author":"GR Locke","year":"2003","unstructured":"Locke GR, Zinsmeister AR, Talley NJ. Can symptoms predict endoscopic findings in GERD? Gastrointest Endosc. 2003;58(5):661\u201370.","journal-title":"Gastrointest Endosc"},{"issue":"1","key":"150_CR27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2125.2007.02851.x","volume":"64","author":"J Hughes","year":"2007","unstructured":"Hughes J, Lockhart J, Joyce A. Do calcium antagonists contribute to gastro-oesophageal reflux disease and concomitant noncardiac chest pain? Br J Clin Pharmacol. 2007;64(1):83\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"150_CR28","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1046\/j.1365-2036.2000.00813.x","volume":"14","author":"T Lind","year":"2000","unstructured":"Lind T, Rydberg L, Kyleback A, Jonsson A, Andersson T, Hasselgren G, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000;14(7):861\u20137.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"150_CR29","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00228-004-0841-1","volume":"60","author":"M Hassan-Alin","year":"2005","unstructured":"Hassan-Alin M, Andersson T, Niazi M, Rohss K. A pharmacokinetic study comparing single and repeated oral doses of 20\u00a0mg and 40\u00a0mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. Eur J Clin Pharmacol. 2005;60(11):779\u201384.","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"150_CR30","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1046\/j.1365-2036.2001.01087.x","volume":"15","author":"T Andersson","year":"2001","unstructured":"Andersson T, Rohss K, Bredberg E, Hassan-Alin M. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther. 2001;15(10):1563\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"150_CR31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000065588","volume":"66","author":"BR Yacyshyn","year":"2002","unstructured":"Yacyshyn BR, Thomson AB. The clinical importance of proton pump inhibitor pharmacokinetics. Digestion. 2002;66(2):67\u201378.","journal-title":"Digestion"},{"key":"150_CR32","unstructured":"Nexium Control (esomeprazole) [summary of product characteristics]. Kent, United Kingdom: Pfizer Consumer Healthcare Ltd.; 2014."},{"key":"150_CR33","unstructured":"Losec (omeprazole) [summary of product characteristics]. Bedforshire, United Kingdom: AstraZeneca UK Limited; 2014."},{"issue":"8","key":"150_CR34","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1155\/1997\/830856","volume":"11","author":"AB Thomson","year":"1997","unstructured":"Thomson AB, Sinclair P, Matisko A, Rosen E, Andersson T, Olofsson B. Influence of food on the bioavailability of an enteric-coated tablet formulation of omeprazole 20\u00a0mg under repeated dose conditions. Can J Gastroenterol. 1997;11(8):663\u20137.","journal-title":"Can J Gastroenterol"},{"issue":"7","key":"150_CR35","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00228-002-0502-1","volume":"58","author":"O Junghard","year":"2002","unstructured":"Junghard O, Hassan-Alin M, Hasselgren G. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH. Eur J Clin Pharmacol. 2002;58(7):453\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"150_CR36","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1046\/j.1365-2036.2000.00829.x","volume":"14","author":"JG Hatlebakk","year":"2000","unstructured":"Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000;14(10):1267\u201372.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"150_CR37","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2165\/00044011-200828060-00001","volume":"28","author":"C Wilder-Smith","year":"2008","unstructured":"Wilder-Smith C, Backlund A, Eckerwall G, Lind T, Fjellman M, Rohss K. Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study. Clin Drug Investig. 2008;28(6):333\u201343.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"150_CR38","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/00365520601075845","volume":"42","author":"C Wilder-Smith","year":"2007","unstructured":"Wilder-Smith C, Lind T, Lundin C, Naucler E, Nilsson-Pieschl C, Rohss K. Acid control with esomeprazole and lansoprazole: a comparative dose-response study. Scand J Gastroenterol. 2007;42(2):157\u201364.","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"150_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00044011-200424010-00001","volume":"24","author":"K Rohss","year":"2004","unstructured":"Rohss K, Wilder-Smith C, Naucler E, Jansson L. Esomeprazole 20\u00a0mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin Drug Investig. 2004;24(1):1\u20137.","journal-title":"Clin Drug Investig"},{"key":"150_CR40","unstructured":"Egapal (omeprazole) [Italian summary of product characteristics]. Origgio, Italy: Sandoz SpA Largo U; 2012."},{"key":"150_CR41","unstructured":"Pantoloc Control [summary of product characteristics]. Konstanz, Germany: Takeda GmbH; 2014."},{"issue":"4","key":"150_CR42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3810\/pgm.2014.07.2781","volume":"126","author":"DA Peura","year":"2014","unstructured":"Peura DA, Traxler B, Kocun C, Lind T. Esomeprazole treatment of frequent heartburn: two randomized, double-blind, placebo-controlled trials. Postgrad Med. 2014;126(4):33\u201341.","journal-title":"Postgrad Med"},{"issue":"9","key":"150_CR43","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1046\/j.1365-2036.1998.00381.x","volume":"12","author":"A Dettmer","year":"1998","unstructured":"Dettmer A, Vogt R, Sielaff F, Luhmann R, Schneider A, Fischer R. Pantoprazole 20\u00a0mg is effective for relief of symptoms and healing of lesions in mild reflux oesophagitis. Aliment Pharmacol Ther. 1998;12(9):865\u201372.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"150_CR44","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1046\/j.1365-2036.2003.01771.x","volume":"18","author":"PO Katz","year":"2003","unstructured":"Katz PO, Castell DO, Levine D. Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther. 2003;18(9):875\u201382.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"150_CR45","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2710.2004.00620.x","volume":"30","author":"LD Allgood","year":"2005","unstructured":"Allgood LD, Grender JM, Shaw MJ, Peura DA. Comparison of Prilosec OTC (omeprazole magnesium 20.6\u00a0mg) to placebo for 14\u00a0days in the treatment of frequent heartburn. J Clin Pharm Ther. 2005;30(2):105\u201312.","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"150_CR46","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3810\/pgm.2009.07.2019","volume":"121","author":"PR Kushner","year":"2009","unstructured":"Kushner PR, Snoddy AM, Gilderman L, Peura DA. Lansoprazole 15\u00a0mg once daily for 14\u00a0days is effective for treatment of frequent heartburn: results of 2 randomized, placebo-controlled, double-blind studies. Postgrad Med. 2009;121(4):67\u201375.","journal-title":"Postgrad Med"},{"issue":"7","key":"150_CR47","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/j.1572-0241.2003.07531.x","volume":"98","author":"R Shaker","year":"2003","unstructured":"Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol. 2003;98(7):1487\u201393.","journal-title":"Am J Gastroenterol"},{"key":"150_CR48","doi-asserted-by":"crossref","unstructured":"Johnson DA, Le Moigne A, Hugo V, Nagy P. Relief and resolution of GERD-related sleep disturbances with esomeprazole 20\u00a0mg: results from two randomized, double-blind trials in subjects with frequent nighttime heartburn and associated sleep disturbance [poster]. Digestive Disease Week 2014; Chicago, IL. 2014.","DOI":"10.1016\/S0016-5085(14)62746-3"},{"issue":"9","key":"150_CR49","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/j.1572-0241.2005.00285.x","volume":"100","author":"DA Johnson","year":"2005","unstructured":"Johnson DA, Orr WC, Crawley JA, Traxler B, McCullough J, Brown KA, et al. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am J Gastroenterol. 2005;100(9):1914\u201322.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"150_CR50","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1365-2036.2010.04339.x","volume":"32","author":"D Johnson","year":"2010","unstructured":"Johnson D, Crawley JA, Hwang C, Brown K. Clinical trial: esomeprazole for moderate-to-severe nighttime heartburn and gastro-oesophageal reflux disease-related sleep disturbances. Aliment Pharmacol Ther. 2010;32(2):182\u201390.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"150_CR51","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1365-2036.1995.tb00437.x","volume":"9","author":"R Corinaldesi","year":"1995","unstructured":"Corinaldesi R, Valentini M, Belaiche J, Colin R, Geldof H, Maier C. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. Aliment Pharmacol Ther. 1995;9(6):667\u201371.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"150_CR52","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2036.2006.03129.x","volume":"25","author":"PB Miner Jr","year":"2007","unstructured":"Miner PB Jr, Allgood LD, Grender JM. Comparison of gastric pH with omeprazole magnesium 20.6\u00a0mg (Prilosec OTC) o.m. famotidine 10\u00a0mg (Pepcid AC) b.d. and famotidine 20\u00a0mg b.d. over 14\u00a0days of treatment. Aliment Pharmacol Ther. 2007;25(1):103\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"150_CR53","doi-asserted-by":"crossref","first-page":"548","DOI":"10.5414\/CPP44548","volume":"44","author":"E Salgueiro","year":"2006","unstructured":"Salgueiro E, Rubio T, Hidalgo A, Manso G. Safety profile of proton pump inhibitors according to the spontaneous reports of suspected adverse reactions. Int J Clin Pharmacol Ther. 2006;44(11):548\u201356.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"150_CR54","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.phrs.2008.09.016","volume":"59","author":"V Savarino","year":"2009","unstructured":"Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. Pharmacol Res. 2009;59(3):135\u201353.","journal-title":"Pharmacol Res"},{"key":"150_CR55","unstructured":"Zolt [summary of product characteristics]. Espoo, Finland: Orion Corporation; 2013."},{"issue":"4","key":"150_CR56","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.surg.2013.07.020","volume":"154","author":"MJ Lada","year":"2013","unstructured":"Lada MJ, Nieman DR, Han M, Timratana P, Alsalahi O, Peyre CG, et al. Gastroesophageal reflux disease, proton-pump inhibitor use and Barrett\u2019s esophagus in esophageal adenocarcinoma: trends revisited. Surgery. 2013;154(4):856\u201366.","journal-title":"Surgery"},{"issue":"4","key":"150_CR57","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.cgh.2012.11.014","volume":"11","author":"F Kastelein","year":"2013","unstructured":"Kastelein F, Spaander MC, Steyerberg EW, Biermann K, Valkhoff VE, Kuipers EJ, et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett\u2019s esophagus. Clin Gastroenterol Hepatol. 2013;11(4):382\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"150_CR58","doi-asserted-by":"crossref","first-page":"272","DOI":"10.4082\/kjfm.2012.33.5.272","volume":"33","author":"JS Ahn","year":"2012","unstructured":"Ahn JS, Park SM, Eom CS, Kim S, Myung SK. Use of proton pump inhibitor and risk of colorectal cancer: a meta-analysis of observational studies. Korean J Fam Med. 2012;33(5):272\u20139.","journal-title":"Korean J Fam Med"},{"issue":"7","key":"150_CR59","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1136\/gut.52.7.942","volume":"52","author":"DN Bateman","year":"2003","unstructured":"Bateman DN, Colin-Jones D, Hartz S, Langman M, Logan RF, Mant J, et al. Mortality study of 18 000 patients treated with omeprazole. Gut. 2003;52(7):942\u20136.","journal-title":"Gut"},{"issue":"1","key":"150_CR60","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1542-3565(03)00287-8","volume":"2","author":"AM Fendrick","year":"2004","unstructured":"Fendrick AM, Shaw M, Schachtel B, Allgood L, Allgood G, Grender J, et al. Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn. Clin Gastroenterol Hepatol. 2004;2(1):17\u201321.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"150_CR61","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/00005650-199009000-00012","volume":"28","author":"G Oster","year":"1990","unstructured":"Oster G, Huse DM, Delea TE, Colditz GA, Richter JM. The risks and benefits of an Rx-to-OTC switch. The case of over-the-counter H2-blockers. Med Care. 1990;28(9):834\u201352.","journal-title":"Med Care"},{"issue":"6","key":"150_CR62","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1365-2036.2006.03084.x","volume":"24","author":"E Bjornsson","year":"2006","unstructured":"Bjornsson E, Abrahamsson H, Simren M, Mattsson N, Jensen C, Agerforz P, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006;24(6):945\u201354.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"150_CR63","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S1542-3565(05)00023-6","volume":"3","author":"KR McQuaid","year":"2005","unstructured":"McQuaid KR, Laine L. Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials. Clin Gastroenterol Hepatol. 2005;3(6):553\u201363.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-015-0150-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-015-0150-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-015-0150-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T17:06:13Z","timestamp":1717952773000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-015-0150-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,23]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["150"],"URL":"https:\/\/doi.org\/10.1007\/s11096-015-0150-z","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,23]]}}}